Market Overview

Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT

Rodman & Renshaw reiterated its Cytokinetics (NASDAQ: CYTK) Market Outperform rating and $4 price target in a research report published today.

Posted-In: Price Target Reiteration Analyst Ratings

 

Most Popular

Related Articles (CYTK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters